Novo Nordisk Trims US Workforce While Buyback Tops 35 Million Shares
Published on 10/05/2026 at 13:41 | Editorial boerse-global.de
Novo Nordisk is pressing ahead with a dual strategy of cost discipline and pipeline expansion, even as its shares remain stuck roughly a quarter below where they started the year. The Danish drugmaker disclosed plans to cut 108 positions at its US headquarters in Plainsboro, New Jersey, according to a filing with the state's Department of Labor & Workforce Development. The reductions are slated for completion by December 31 and reflect a recalibration of regional administrative needs as the company reshapes its American operations.
The workforce move lands alongside a steady capital-return program. Between early February and September 25, Novo Nordisk repurchased 35,379,179 of its own shares for a total of DKK 9,939,842,031. The buyback underscores management's willingness to keep funneling cash back to shareholders even while development spending stays elevated.
FDA Review Extended on Hemophilia A Candidate
On the regulatory front, investors will have to wait longer for Denecimig, the company's hemophilia A treatment. The US Food and Drug Administration has extended its review of the drug, citing the need for remediation work at a manufacturing facility, Novo Nordisk said Friday. Crucially, the agency flagged no deficiencies in the efficacy or safety data submitted, and it has not yet set a new date for a final decision.
That distinction matters for the Copenhagen-based group, which is working to broaden its portfolio beyond the weight-loss and diabetes franchises that made it a household name. The delay is a timing setback rather than a scientific one, and Novo Nordisk said the extended review does not affect its financial outlook for 2026. Subject to approval, the company still aims to launch Denecimig in the US during the first half of 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Real-World Data and a Chinese Licensing Deal
Beyond its own labs, Novo Nordisk is leaning on outside evidence and external science. On September 30, it published results from the OCTANE study, which draws on anonymized treatment data from the telehealth platform Ro. The research offers a window into how its products perform in everyday practice, complementing the company's formal clinical trial program.
Roughly a week earlier, the group secured exclusive development and marketing rights to HRS-1596, an oral candidate from Jiangsu Hengrui Pharmaceuticals. The license covers markets worldwide outside mainland China, Hong Kong, Macau and Taiwan. Since that deal was announced, the stock has shed 2.2%.
Long-Range Targets and Market Headwinds
Management continues to hold to ambitious long-term goals: more than five so-called multi-blockbusters on the market by 2030 and treatment for over 60 million patients globally. Executives have been explicit that these figures carry uncertainty and should not be read as financial guidance.
Sentiment around the stock remains subdued. The shares closed Friday at EUR 33.06 and traded at EUR 33.02 at the start of the week. Worries over future pricing pressure, expiring patents on semaglutide and competition from Eli Lilly have weighed on the valuation, according to Reuters. Whether Novo Nordisk can clear the manufacturing issues on schedule will go a long way toward determining if Denecimig's US debut stays on track for 2027.
Ad
Novo Nordisk Stock: New Analysis - 5 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
